The GLP-1 and Multi-Agonist Pipeline Timeline: What's Actually Coming Through 2028
Research context and evidence limits. Retatrutide references do not establish availability, comparative superiority or instructions for personal use.
FormBlends Editorial Research · Updated 2026-09-27
Retatrutide research context
Retatrutide is investigational, is not FDA-approved and cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell it. Percentages from separate trials do not establish superiority, and an average does not predict an individual outcome. The cited evidence does not establish sex-specific regimens or validate combinations with other drugs. No FDA approval date has been established.
Key Takeaways
- The investigational obesity drug pipeline is the deepest it has ever been: at least six advanced candidates in or near phase 3
- CagriSema is under FDA review; a 2026 launch is plausible if approved
- Survodutide brings a MASH liver-disease angle that distinguishes it from competitors
- Danuglipron has been discontinued; mazdutide is China-only with no U.S. development plan
Direct answer
Table of contents
- The full pipeline at a glance
- Already-approved drugs as the baseline
- CagriSema: the closest to U.S. approval
- Survodutide: the MASH-focused dual agonist
- Oral GLP-1s: orforglipron and oral semaglutide 50 mg
- Mazdutide: approved in China, not in the U.S.
- Discontinued and stalled candidates
- What it all means for patients
- The contrary view: are too many similar drugs in development?
- FAQ
- Sources
The full pipeline at a glance
| Drug | Sponsor | Mechanism | Route | Stage (May 2026) | Possible U.S. approval window |
|---|---|---|---|---|---|
| CagriSema | Novo Nordisk | GLP-1 + amylin (combo) | Once-weekly injection | FDA review | Late 2026 to early 2027 |
| Survodutide | Boehringer / Zealand | GLP-1 / glucagon | Once-weekly injection | Phase 3 (SYNCHRONIZE) | 2027-2028 |
| Orforglipron | Eli Lilly | GLP-1 (small molecule) | Once-daily oral | Phase 3 | 2026-2027 |
| Oral semaglutide 50 mg | Novo Nordisk | GLP-1 (peptide) | Once-daily oral | Filed | 2026 |
| Mazdutide | Lilly / Innovent | GLP-1 / glucagon | Once-weekly injection | Approved in China; no U.S. plan | Not on U.S. path |
| Danuglipron | Pfizer | GLP-1 (small molecule) | Oral | Discontinued | Not coming |
| Pemvidutide | Altimmune | GLP-1 / glucagon | Once-weekly injection | Phase 2 / early phase 3 | 2028+ |
| Bimagrumab | Versanis / Lilly | Activin receptor (lean mass preservation) | Monthly infusion | Phase 2 / phase 3 | 2028+ |
Approval windows are speculative and based on standard regulatory timelines. Actual outcomes depend on trial results, FDA review pace, and sponsor strategy.
Already-approved drugs as the baseline
The pipeline only makes sense in the context of what is already on the market.
| Drug | Brand | Mechanism | FDA approval (obesity) | Weight loss in pivotal trial |
|---|---|---|---|---|
| Liraglutide | Saxenda | GLP-1 | December 2014 | ~8% (SCALE) |
| Semaglutide | Wegovy | GLP-1 | June 2021 | ~14.9% (STEP 1) |
| Tirzepatide | Zepbound | GLP-1 / GIP | November 2023 | ~22.5% at 15 mg (SURMOUNT-1) |
These three injectable GLP-1 class drugs anchor the current market. The pipeline drugs aim to beat them on weight loss, convenience (oral options), specific indications (MASH), or some combination.
CagriSema: the closest to U.S. approval
Novo Nordisk filed CagriSema (semaglutide 2.4 mg + cagrilintide 2.4 mg) with the FDA during 2025. Phase 3 REDEFINE-1 reported ~22.7% mean weight loss at 68 weeks.
What to watch:
- FDA action date in 2026 (most likely)
- Commercial launch shortly after approval
- Pricing position relative to Wegovy and Zepbound
- Insurance coverage dynamics, which typically lag launch by 6-18 months
CagriSema's positioning: a Novo product that produces tirzepatide-comparable weight loss through a different mechanism (GLP-1 plus amylin). The main commercial questions are pricing and how Novo positions it alongside Wegovy.
Expected timeline:
- Phase 3 readouts in waves through 2025-2026
- FDA filing potentially in 2026-2027
- Possible FDA approval in 2027
- Commercial launch within weeks of approval
Survodutide: the MASH-focused dual agonist
Boehringer Ingelheim's survodutide (BI 456906) is a GLP-1/glucagon dual agonist developed for obesity, type 2 diabetes, and MASH liver disease.
Phase 2 data:
- Obesity: ~19% weight loss at 4.8 mg over 46 weeks
- MASH: substantial histological resolution and fibrosis improvement
The phase 3 SYNCHRONIZE program is running through 2025-2027. Survodutide's distinctive value is the MASH liver indication, which competitors do not directly target.
Expected timeline: phase 3 readouts 2025-2027; FDA filing 2026-2027; possible approval 2027-2028.
Oral GLP-1s: orforglipron and oral semaglutide 50 mg
The race to the first oral GLP-1 specifically for obesity has two leading contenders.
Orforglipron. Eli Lilly's once-daily oral small-molecule GLP-1 agonist. Phase 2 produced ~14% weight loss at 36 weeks at the highest dose. Phase 3 ongoing. Possible filing in 2025-2026.
Oral semaglutide 50 mg. Novo Nordisk's higher-dose oral semaglutide (peptide with absorption enhancer). The OASIS phase 3 program reported ~15% weight loss at 68 weeks. Filed with FDA.
Both products would be the first oral GLP-1 specifically labeled for obesity. The competitive position depends on tolerability, convenience (orforglipron has fewer food-fasting requirements than oral semaglutide), and pricing.
Expected timeline: 2026-2027 for the first approval of either.
Mazdutide: approved in China, not in the U.S.
Mazdutide (LY3305677) is a GLP-1/glucagon dual agonist that Eli Lilly licensed to Innovent Biologics for China. The DREAMS-1 phase 3 reported ~14.4% weight loss at 9 mg over 48 weeks. China's NMPA approved mazdutide for obesity in 2025 under the brand Sineipasy.
Discontinued and stalled candidates
Several oral GLP-1 candidates have failed or been deprioritized:
- Danuglipron (Pfizer). Discontinued December 2023 due to tolerability. Once-daily reformulation paused 2024-2025
- Several other early-phase Pfizer candidates have been deprioritized as Pfizer's obesity portfolio remained smaller than peers
- Other small-molecule oral GLP-1 candidates from various companies have stalled or been deprioritized
The discontinuation pattern reflects the difficulty of developing tolerable oral GLP-1 drugs in a market with high-efficacy injectable competition.
What it all means for patients
From a U.S. patient perspective, the practical implications of the pipeline:
Implication 1: More options coming. Through 2028, the U.S. obesity drug market should expand from 3 leading drugs (Wegovy, Zepbound, Saxenda) to 6-8 leading drugs spanning multiple mechanisms and routes of administration.
Implication 2: Oral options imminent. The first FDA-approved oral GLP-1 for obesity is likely in 2026-2027. For patients with injection aversion, this is a meaningful change.
Implication 5: Pricing may not improve much. Despite more competition, list prices have not fallen meaningfully. New drugs typically launch near existing competitor pricing.
The contrary view: are too many similar drugs in development?
A fair critique of the obesity pipeline:
Argument 1: Mechanism similarity. Most pipeline drugs are GLP-1 class derivatives with modest variations. The marginal therapeutic gain may not justify the development cost compared to fundamentally different approaches.
Argument 2: Patient population overlap. The drugs largely target the same obesity population. Differentiation comes through marketing more than through clinical positioning.
Argument 3: Pricing pressure absent. Despite increased competition, list prices have not fallen. Patient-level cost remains a major access barrier.
Argument 4: Long-term safety lag. All these drugs are chronic medications. Long-term safety data accumulates only over years. Approving more drugs in the same class without strong long-term data raises questions about post-marketing surveillance capacity.
The counterargument: obesity is a chronic disease affecting hundreds of millions globally. More options means better matching of drug to patient phenotype. Tolerability differences between drugs matter at the individual level even when population averages converge.
Decision framework
If you need treatment now: Wegovy and Zepbound are the leading approved options. There is no clinical case for waiting.
If you're on a current GLP-1 and considering switching when a new drug launches: the case for switching depends on tolerability problems, plateau, or specific indication needs. Most patients on a working regimen should stay.
If you have MASH: resmetirom is approved; survodutide is the leading investigational candidate for the obesity-plus-MASH phenotype.
If you have established cardiovascular disease: semaglutide has the strongest CV evidence today (SELECT). The CV evidence for newer drugs is still accruing.
If you want an oral option: waiting for orforglipron or oral semaglutide 50 mg is reasonable. Until then, Rybelsus (off-label for weight loss in many cases) is the only U.S.-approved oral GLP-1 of any kind.
Compounded medication note for this topic
For The GLP-1 and Multi-Agonist Pipeline Timeline: What's Actually Coming Through 2028, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.
FAQ
What is the next obesity drug to be FDA-approved?
Most likely CagriSema in late 2026.
What is the most powerful obesity drug in development?
Unlikely. New obesity biologics typically launch at or above existing competitor pricing.
Not until FDA approval, expected 2027 in the favorable case. Clinical trial enrollment is the pre-approval route.
Is mazdutide better than tirzepatide?
No head-to-head data, and mazdutide is not U.S.-available. Cross-trial estimates favor tirzepatide on weight loss.
What's the difference between dual and triple agonists?
Are there any new mechanisms beyond GLP-1 class?
Yes. Bimagrumab (lean mass preservation), pemvidutide (GLP-1/glucagon), and earlier-phase candidates target adjacent or distinct mechanisms.
Will compounded versions of these drugs be available?
Generally no. Compounded versions of FDA-approved drugs can exist during shortages; compounded versions of investigational drugs do not have a legitimate regulatory path.
Will insurance cover the new drugs?
Coverage typically lags launch by 6-18 months. Commercial coverage will expand; Medicare and Medicaid coverage remains constrained for obesity indications specifically.
Should I be on a clinical trial waiting list?
Trials enroll on a rolling basis. ClinicalTrials.gov is the official source. Participation is one of the few pre-approval access routes.
What about long-term safety?
The longest GLP-1 class data is for semaglutide (~5 years post-approval, ~10 years total since first FDA approval). Newer drugs accumulate less data; post-marketing surveillance is the relevant tool.
Related guides
- What Is Survodutide? A Dual GLP-1/Glucagon Agonist Built for More Than Weight Loss
- Tool: weight-loss timeline tool
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
- Garvey WT et al. CagriSema REDEFINE-1 Results. ObesityWeek 2024.
- le Roux CW et al. Survodutide for obesity (phase 2). Lancet. 2024.
- Sanyal AJ et al. Survodutide in MASH and Liver Fibrosis (phase 2). NEJM. 2024.
- Wharton S et al. Orforglipron for Adults with Obesity (phase 2). NEJM. 2023.
- Knop FK et al. Oral semaglutide 50 mg in overweight or obesity (OASIS 1). Lancet. 2023.
- Ji L et al. Mazdutide for chronic weight management in Chinese adults (DREAMS-1). 2024-2025.
- Pfizer Inc. Danuglipron Discontinuation Announcement. December 2023.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes (SELECT). NEJM. 2023.
- Harrison SA et al. Resmetirom for NASH with Liver Fibrosis (MAESTRO-NASH). NEJM. 2024.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.
Footer disclaimers
Results Disclaimer. Trial weight-loss percentages cited are population means in controlled trial settings. Real-world outcomes commonly fall below trial averages. Approval timelines can shift; projected dates are not guaranteed.